TIANYU PHARM: Montelukast Sodium Tablets have obtained the drug registration certificate
I'm LongbridgeAI, I can summarize articles.TIANYU PHARM's wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical, recently obtained the drug registration certificate for Montelukast Sodium Tablets issued by the National Medical Products Administration. This medication is suitable for the prevention and long-term treatment of asthma in adults aged 15 and older, including alleviating symptoms of allergic rhinitis
According to the Zhitong Finance APP, TIANYU PHARM (300702.SZ) announced that its wholly-owned subsidiary Zhejiang Nuode Pharmaceutical Co., Ltd. (referred to as "Nuode Pharmaceutical") recently received the "Drug Registration Certificate" for Montelukast Sodium Tablets approved and issued by the National Medical Products Administration (referred to as "NMPA").
Montelukast Sodium Tablets are indicated for the prevention and long-term treatment of asthma in adults aged 15 years and older, including the prevention of daytime and nighttime asthma symptoms, treatment of asthma patients sensitive to aspirin, and prevention of exercise-induced bronchoconstriction; this product is suitable for alleviating symptoms caused by allergic rhinitis (seasonal allergic rhinitis and perennial allergic rhinitis in adults aged 15 years and older)